Comparison of immunogenic potentials of bovine thrombin preparations

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 1, 2009, Pages 41-49

  Zhu, He ^a   Hoppensteadt, Debra ^a   Adiguzel, Cafer ^a   Bick, Rodger L ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine thrombin; Factor Va; Immunoglobulin G; Topical hemostatic agents; Western blot

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 5A ANTIGEN; IMMUNOGLOBULIN G; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COW; CROSS REACTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CATTLE; FACTOR VA; FILTRATION; HEMOSTATICS; IMMUNOGLOBULIN G; RABBITS; THROMBIN;

EID: 58449109451     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608327863     Document Type: Article

References (28)

1. Schoenecker JG, Hauck RK, Mercer MC, Parker W., Lawson JH Exposure to topical bovine thrombin during surgery elicits a response against the xenogenic carbohydrate galactose(alpha1-3)galactose. J Clin Immunol. 2000 ; 20: 434-444.
2. Lawson JH The clinical use and immunologic impact of thrombin in surgery. Semin Thromb hemost. 2006 ; 32 (suppl 1). 98-110.
3. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001 ; 58: 710-719.
4. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol. 1994 ; 45: 128-135.
5. Rapaport SI, Zivelin A., Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992 ; 97: 84-91.
6. Cmolik BL, Spero JA, Magovern GJ, Clark RE Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac cardiovasc Surg. 1993 ; 105: 222-228.
7. Chouhan VD, De la cadena RA, Nagaswami C., Weisel JW, Kajani M., Rao AK Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V after exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost. 1997 ; 77: 343-349.
8. Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990 ; 76: 2011-2016.
9. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001 ; 233: 88-96.
10. Streiff MB, Ness PM Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002 ; 42: 18-26.
11. Chapman WC, Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ; 205: 256-265.
12. Weaver FA, Lew W., Granke K., et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg. 2008 ; 47: 1266-1273.
13. Dorion RP, Hamati HF, Landis B., Frey C., Heydt D., Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med. 1998 ; 122: 887-894.
14. Banninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Hematol. 1993 ; 85: 528-532.
15. Knobl P., Lechner K. Acquired factor V inhibitors. Baillieres Clin Hematol. 1998 ; 11: 305-318.
16. Tadokoro K., Ohtoshi T., Takafuji S., et al. Topical thrombin-induced IgE-mediated anaphylaxis. RAST analysis and skin test studies. J Allergy Clin Immunol. 1991 ; 88: 620-629.
17. Esmon CT The subunit structure of thrombin-activated factor V. J Biol Chem. 1979 ; 254: 964-973.
18. Nesheim ME, Mann KG Thrombin catalyzed activation of single chain bovine factor V. J Biol Chem. 1979 ; 254: 1326-1334.
19. Suzuki K., Dahlback B., Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982 ; 257: 6556-6564.
20. Nesheim ME, Tracy PR, Mann KG ''Clotspeed,'' A mathematical stimulation of the functional properties of prothrombinase. J Biol Chem. 1984 ; 259: 1447-1453.
21. Flahert MJ, Henderson R., Wener MH Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med. 1989 ; 111: 631-634.
22. Stricker RB, Lane PK, Leffert JD, Rodgers GM, Shuman MA, Corash L. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood. 1988 ; 72: 1375-1380.
23. Feinstein DI, Rapaport SI, McGehee WG, Patch MJ Factor V anticoagulants: clinical, biochemical and immunochmical observations. J Clin Invest. 1970 ; 49: 1578-1588.
24. Onuora CA, Lindenbaum J., Nossel HL Case report: massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci. 1973 ; 265: 407-417.
25. Coots MC, Muhleman AF, Gluck HI Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol. 1978 ; 4: 193-206.
26. Terrab A., Pawlak D., Spaay P., Hoppensteadt D., Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost. 2008 ; 14: 135-140.
27. Zhu H., Hoppensteadt D., Cunanan J., et al. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application. Clin Appl Thromb Hemost, first published 30th October 2008, DOI: 10.1177/1076029608322550.
28. Sandermann H. Jr, Stromiger JL Purification and properties of C 55-isoprenoid alcohol phosphokinase from Staphylococcus aureus. J Biol Chem. 1972 ; 247: 5123-5131.